Skip to main content

Exenatide News (Page 2)

FDA Approves Bydureon Pen for Once-Weekly Treatment of Adults with Type 2 Diabetes

Monday March 3, 2014 – AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved the Bydureon Pen (exenatide extended-release for injectable suspension) 2 mg as an...

FDA Medwatch Alert: Incretin Mimetic Drugs for Type 2 Diabetes: Early Communication - Reports of Possible Increased Risk of Pancreatitis and Pre-cancerous Findings of the Pancreas

ISSUE: FDA is evaluating unpublished new findings by a group of academic researchers that suggest an increased risk of pancreatitis and pre-cancerous cellular changes called pancreatic duct...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Diabetes, Type 2

Related drug support groups

Bydureon

Exenatide patient information at Drugs.com